Gynaecomastia in the army is a topic that many servicemen find difficult to raise, yet it is more common than widely acknowledged. Gynaecomastia — the benign enlargement of male glandular breast tissue — can affect personnel at any stage of their career, causing physical discomfort and significant psychological distress. From anabolic steroid misuse to prescribed medications and underlying hormonal conditions, the causes are varied and often treatable. This article explains what gynaecomastia is, why it affects some servicemen, what treatment options are available through the NHS and Defence Medical Services, and how it may interact with Army medical fitness standards.

What Is Gynaecomastia and Why Does It Affect Some Servicemen

Gynaecomastia is benign enlargement of male glandular breast tissue caused by a relative excess of oestrogen over androgen activity; it affects servicemen due to factors including weight change, alcohol use, medications, and underlying medical conditions.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery disc of tissue beneath one or both nipples, which may be tender on palpation. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular proliferation and is more common in individuals with higher body fat percentages. Clinically, true gynaecomastia can usually be distinguished by palpating a firm subareolar disc; pseudogynaecomastia feels softer and more diffuse.

The condition can affect males at any age. It is particularly prevalent during three physiological windows: the neonatal period (due to maternal oestrogens), adolescence (when it affects an estimated 50–70% of boys to some degree and typically resolves spontaneously within 6–18 months), and in men over 50 (owing to age-related changes in the testosterone-to-oestrogen ratio). In the majority of adolescent cases, no treatment is required beyond reassurance and monitoring.

The underlying mechanism involves an imbalance between oestrogen and androgen activity at the breast tissue level. Even small relative increases in oestrogen — or reductions in testosterone — can stimulate glandular growth. For serving personnel, this hormonal balance may be disrupted by a range of factors including significant weight change, alcohol use, certain medications, or underlying medical conditions, rather than military service itself being a direct hormonal stressor.

For personnel serving in the British Army, gynaecomastia can be a source of significant psychological distress, affecting self-confidence, body image, and willingness to participate in communal activities such as physical training or shared washing facilities. Despite being a common and largely benign condition, many servicemen feel reluctant to seek medical advice due to stigma or concerns about how it may affect their military career. Understanding the condition clearly is the first step towards appropriate management and reassurance.

Common Causes of Gynaecomastia in Military Personnel

The most clinically significant causes in Army personnel include anabolic-androgenic steroid misuse, certain prescribed medications, chronic alcohol use, unlicensed nutritional supplements, obesity, and underlying conditions such as hypogonadism or liver disease.

Gynaecomastia in military personnel can arise from many of the same causes seen in the general population, but certain factors are particularly relevant in an Army context. The most important causes include:

• Anabolic-androgenic steroid (AAS) misuse: Illicit use of performance-enhancing drugs remains a concern in some military environments. AAS can be aromatised to oestrogen in peripheral tissues, directly causing gynaecomastia. Withdrawal of AAS can also trigger a rebound hormonal imbalance. AAS misuse also carries serious consequences under Army drug policy (see JSP 835).

• Medications: A range of prescribed and over-the-counter drugs are associated with gynaecomastia. UK-relevant examples include spironolactone, antiandrogens (such as bicalutamide and finasteride/dutasteride), some antipsychotics, certain antifungals (including ketoconazole), proton pump inhibitors (such as omeprazole), digoxin, some calcium-channel blockers, and certain antiretrovirals (such as efavirenz). Servicemen receiving treatment for mental health conditions, infections, or other conditions should be aware of this potential side effect. Do not stop any prescribed medicine without first speaking to your doctor or pharmacist. If you suspect a medicine is causing gynaecomastia, this should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

• Alcohol misuse: Chronic alcohol consumption impairs hepatic metabolism of oestrogens and can suppress testosterone production, both of which promote breast tissue growth.

• Nutritional supplements: Protein powders, pre-workout formulas, and herbal supplements — widely used in fitness-focused environments — may contain compounds with oestrogenic activity or undisclosed hormonal ingredients. UK Anti-Doping (UKAD) and the MHRA have issued warnings about unlicensed supplements. Servicemen should source supplements only from reputable, batch-tested suppliers and ensure compliance with Army drug policy.

• Obesity: Increased body fat raises peripheral aromatase activity, converting androgens to oestrogens and contributing to true gynaecomastia as well as pseudogynaecomastia.

• Underlying medical conditions: Hypogonadism, hyperthyroidism, liver disease, and rarely testicular or adrenal tumours can all cause gynaecomastia and must be excluded through appropriate investigation.

It is also worth noting that a significant proportion of cases — particularly in younger recruits — represent physiological gynaecomastia, which resolves spontaneously without intervention. However, any new or progressive breast swelling warrants clinical evaluation to rule out pathological causes.

Although rare, male breast cancer must be considered, particularly in older men, those with a family history of breast cancer, known BRCA2 mutations, or Klinefelter syndrome. Any suspicious features (see the final section) should prompt urgent assessment.

Treatment Options Available Through the NHS and Defence Medical Services

Management depends on cause and duration; options include treating the underlying cause, off-label tamoxifen or raloxifene in the active phase, and subcutaneous mastectomy for longstanding cases, accessed via DMS or NHS referral pathways.

The management of gynaecomastia depends on the underlying cause, duration of symptoms, and degree of physical or psychological impact. For servicemen, care may be accessed through the Defence Medical Services (DMS), which operates in alignment with NHS clinical standards and NICE guidance.

Initial assessment typically involves a thorough history, physical examination (including examination of the testes), and targeted investigations, which may include:

• Morning serum total testosterone (with LH and FSH), oestradiol, and prolactin

• Beta-hCG (to exclude hCG-secreting germ cell tumours)

• Sex hormone-binding globulin (SHBG) where clinically indicated

• Liver function tests, renal function, and thyroid function tests

• Testicular ultrasound if a testicular mass or tumour is suspected

• Breast imaging (mammography and/or ultrasound) at a symptomatic breast clinic if malignancy is suspected

Where red-flag features are present (see the final section), referral under the NICE NG12 urgent suspected cancer pathway (2-week wait) to a symptomatic breast clinic should be made without delay.

Where an underlying cause is identified — such as a medication side effect or hormonal disorder — treating the root cause is the primary approach and may lead to spontaneous resolution of breast tissue enlargement.

For persistent or symptomatic gynaecomastia, pharmacological options include tamoxifen (an oestrogen receptor antagonist) or raloxifene (a selective oestrogen receptor modulator), both of which have demonstrated efficacy in reducing glandular tissue, particularly when used in the early, active phase of the condition. These medicines are used off-label in the UK for this indication and should be initiated and monitored by a specialist. Important safety considerations include an increased risk of venous thromboembolism (VTE) with tamoxifen; a full risk assessment and informed consent discussion should take place before prescribing. Refer to the BNF and the relevant Summary of Product Characteristics (SmPC, available at medicines.org.uk) for full prescribing information. Aromatase inhibitors have limited evidence for gynaecomastia and are not generally recommended outside specialist settings.

When gynaecomastia is longstanding (typically beyond 12 months), fibrous tissue replaces active glandular tissue and medical therapy becomes less effective. In such cases, surgical intervention — most commonly subcutaneous mastectomy or liposuction-assisted excision — may be considered. NHS funding for surgery is subject to local Integrated Care Board (ICB) criteria, which vary across England; some ICBs require an Individual Funding Request (IFR) process. Surgery is generally reserved for cases causing significant psychological distress or functional impairment. Servicemen may also access surgical assessment through DMS referral pathways. Information on surgical options and what to expect is available from the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS).

Fitness for Duty and Army Medical Standards for Gynaecomastia

Gynaecomastia alone does not typically cause medical downgrading under PULHHEEMS (JSP 950); however, associated conditions, surgical recovery, or psychological impact may affect grading on an individual basis.

The British Army assesses medical fitness for service using the PULHHEEMS system, as set out in MOD Joint Service Publication JSP 950 (Medical Policy). This standardised framework evaluates physical capacity, upper and lower limb function, hearing, eyesight, mental health, and stability. Gynaecomastia itself is not usually a direct cause of medical downgrading in the absence of functional impairment or significant underlying pathology; however, grading decisions are made on an individual basis by the Medical Officer (MO) or Senior Medical Officer (SMO) and will take into account any associated conditions or treatment requirements.

Relevant considerations include:

• Confirmed anabolic steroid misuse carries serious disciplinary and administrative consequences under Army drug policy (JSP 835: Alcohol and Substance Misuse and Dependence Policy), entirely separate from any medical management.

• Underlying endocrine disorders such as hypogonadism or hyperthyroidism, if identified as the cause of gynaecomastia, may require ongoing specialist management and could affect medical grading depending on severity and treatment requirements, as assessed under JSP 950.

• Surgical recovery following mastectomy would result in a temporary medical downgrade during the healing period, with return to full duties expected once the MO confirms fitness. The duration of any downgrade is determined on an individual basis.

Psychological impact is also a relevant consideration. If gynaecomastia is contributing to anxiety, depression, or avoidance behaviours that affect operational effectiveness, this should be addressed through the appropriate mental health support channels within the DMS, including referral to a Department of Community Mental Health (DCMH).

It is important to emphasise that seeking medical advice for gynaecomastia will not automatically affect a serviceman's career or deployment status. Early disclosure and appropriate management are strongly encouraged, and medical confidentiality is maintained in line with standard NHS and DMS protocols.

Seeking Support and Next Steps If You Are Affected

Servicemen should speak to their unit Medical Officer or garrison GP as a first step; urgent 2-week-wait referral is indicated if red-flag features such as a hard lump, nipple retraction, or discharge are present.

If you are a serving member of the British Army and are concerned about gynaecomastia, the most important first step is to speak to your unit Medical Officer (MO) or a GP at your garrison medical centre. Early assessment allows for timely identification of any underlying cause and access to appropriate treatment before the condition becomes more established.

Have questions about your medication? Our pharmacists are here to help →

You should seek prompt medical review — and your doctor should consider an urgent 2-week-wait referral to a symptomatic breast clinic in line with NICE NG12 — if you notice any of the following:

• Rapid or asymmetrical breast enlargement

• A hard, irregular, or fixed lump beneath the nipple

• Nipple retraction or skin tethering

• Nipple discharge, particularly if blood-stained

• Axillary lymphadenopathy (swollen lymph nodes in the armpit)

• A firm intratesticular mass or testicular swelling (which warrants urgent testicular ultrasound)

• Systemic symptoms such as unexplained weight loss or fatigue

These features may indicate a more serious underlying condition requiring urgent investigation and should not be ignored.

For those who feel uncomfortable raising the issue with a military medical professional, it is entirely appropriate to consult an NHS GP in confidence. The NHS provides access to endocrinology and general surgery referrals through standard pathways, and NICE guidance supports investigation and onward referral where clinically indicated.

Psychological support is equally important. Organisations such as Combat Stress and the Veterans' Mental Health and Wellbeing Service (Op COURAGE) offer confidential support for serving personnel and veterans experiencing mental health difficulties, including body image concerns. NHS Talking Therapies (formerly IAPT) is also available for non-military consultations and can be self-referred in many areas.

Finally, servicemen are strongly advised to avoid self-medicating with supplements, hormonal compounds, or substances purchased online. Buying selective oestrogen receptor modulators (SERMs) or aromatase inhibitors without a prescription is unsafe and may be unlawful. Such substances can worsen gynaecomastia, introduce additional health risks, and may contravene Army drug policy. If you suspect that a prescribed medicine is causing gynaecomastia, report this via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) and discuss it with your prescriber before making any changes. Evidence-based care, accessed through legitimate medical channels, remains the safest and most effective route to managing this condition.

Frequently Asked Questions